RxDoctor Payments Data

Eliezer Eisenberger

Foot & Ankle Surgery · New York, NYNPI 1518246768

Payments from drug & device makers

$4,186in general payments, 2019–2025

Across 73 payments — averaging $57.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$1K
  • Smith+Nephew$612
  • AbbVie$561
  • Acera Surgical, Inc.$539
  • Organogenesis Inc.$373
  • Linvatec Corporation$137
  • plus $755 from 12 others

What the payments were for

  • Food & beverage$4,186100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,186 in reported general payments places this provider in the 65th percentile of 652 foot & ankle surgery providers in New York.

See all foot & ankle surgery providers in New York

Medicare billing

Part B allowed, 2024
$54,315
Medicare patients
138
Services billed
644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Doxepin Hcl579$59,583
SantylCollagenase Clostridium Hist.15$44,161
Diclofenac Sodium ErDiclofenac Sodium401$31,118
Fluocinonide153$11,202
Ammonium Lactate330$6,298
Clotrimazole212$6,288
Fluconazole54$6,153
Etodolac17$2,541
CiclopiroxCiclopirox Olamine27$1,410
Naproxen Sodium13$1,018
Ketoconazole12$470
ErythromycinErythromycin Base In Ethanol19$420
Mupirocin50$380
Ciclopirox23$283
Terbinafine Hcl29$164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$612$44,16115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 652 foot & ankle surgery providers in New York.

Other foot & ankle surgery in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →